Unesbulin (PTC596) is a novel orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor, Unesbulin downregulating MCL-1 and inducing p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.
Unesbulin (PTC596) is a novel orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor, Unesbulin downregulating MCL-1 and inducing p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.
Unesbulin (PTC596) is a novel orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor, Unesbulin downregulating MCL-1 and inducing p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.
Uniconazole is a plant growth regulator that inhibits cytochrome P450 707As (Ki=68 nM) plays a role, which is a family of enzymes that separate abscisic acid and therefore inhibits the biosynthesis of gibberellin and sterols.
Uniconazole is a plant growth regulator that inhibits cytochrome P450 707As (Ki=68 nM) plays a role, which is a family of enzymes that separate abscisic acid and therefore inhibits the biosynthesis of gibberellin and sterols.
Upacicalcet is a calcium-sensing receptor (CaSR) agonist being developed for the study of secondary hyperparathyroidism (SHPT).
Upacicalcet is a calcium-sensing receptor (CaSR) agonist being developed for the study of secondary hyperparathyroidism (SHPT).
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.